TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immuron ( (IMRN) ) has issued an announcement.
On September 30, 2025, Immuron Limited announced the consent of Grant Thornton Audit Pty Ltd, its independent registered accounting firm, to incorporate their audit report into the company’s registration statement on Form F-3. This consent facilitates the inclusion of Immuron’s financial statements, dated June 30, 2025, into future filings, potentially impacting investor relations and compliance with regulatory requirements.
The most recent analyst rating on (IMRN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Immuron stock, see the IMRN Stock Forecast page.
Spark’s Take on IMRN Stock
According to Spark, TipRanks’ AI Analyst, IMRN is a Neutral.
Immuron’s overall stock score is primarily impacted by its strong revenue growth yet significant challenges in profitability and cash flow, leading to liquidity concerns. The technical analysis presents a neutral outlook with slight downward pressure. The valuation remains unattractive due to a negative P/E ratio and no dividend yield, further weighing down the score.
To see Spark’s full report on IMRN stock, click here.
More about Immuron
Immuron Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of oral immunotherapy products for the treatment of gut-mediated diseases.
Average Trading Volume: 242,307
Technical Sentiment Signal: Sell
Current Market Cap: $13.41M
For an in-depth examination of IMRN stock, go to TipRanks’ Overview page.